Abstract
Adenosines diverse physiological functions are mediated by four subtypes of receptors (A1, A2A, A2B and A3). The A1 adenosine receptor pharmacology and therapeutic application of ligands for this receptor are the subjects of this review. A1 receptors are present on the surface of cells in organs throughout the body. Actions mediated by A1 receptors include slowing of heart rate and AV nodal conduction, reduction of atrial contractility, attenuation of the stimulatory actions of catecholamines on beta-adrenergic receptors, reduction of lipolysis in adipose tissue, reduction of urine formation, and inhibition of neuronal activity. Although adenosine analogs with high efficacy, affinity, and selectivity for the A1 receptor are available, the ubiquitous distribution and wide range of physiological actions mediated by A1 receptors are obstacles to development of therapeutic agents that activate these receptors. However, it may be possible to exploit the high A1 “receptor reserve” for some actions of adenosine by use of weak (partial) agonists to target these actions while avoiding others for which receptor reserve is low. The presence of high receptor reserves for the anti-arrhythmic and anti-lipolytic actions of adenosine suggests that partial A1 agonists could be used as anti-arrhythmic and anti-lipolytic agents. In addition, allosteric enhancers of the binding of adenosine to A1 receptors could be used therapeutically to potentiate desirable effects of endogenous adenosine. Antagonists of the A1 receptor can increase urine formation, and because they do not decrease renal blood flow, are particularly useful to maintain glomerular filtration in patients having edema secondary to reduced cardiac function.
Keywords: adenosine, a1 receptor, anti-arrhythmic, anti-lipolytic, g protein-coupled receptor (gpcr)
Current Topics in Medicinal Chemistry
Title: Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands
Volume: 3 Issue: 4
Author(s): Arvinder K. Dhalla, John C. Shryock, Revati Shreeniwas and Luiz Belardinelli
Affiliation:
Keywords: adenosine, a1 receptor, anti-arrhythmic, anti-lipolytic, g protein-coupled receptor (gpcr)
Abstract: Adenosines diverse physiological functions are mediated by four subtypes of receptors (A1, A2A, A2B and A3). The A1 adenosine receptor pharmacology and therapeutic application of ligands for this receptor are the subjects of this review. A1 receptors are present on the surface of cells in organs throughout the body. Actions mediated by A1 receptors include slowing of heart rate and AV nodal conduction, reduction of atrial contractility, attenuation of the stimulatory actions of catecholamines on beta-adrenergic receptors, reduction of lipolysis in adipose tissue, reduction of urine formation, and inhibition of neuronal activity. Although adenosine analogs with high efficacy, affinity, and selectivity for the A1 receptor are available, the ubiquitous distribution and wide range of physiological actions mediated by A1 receptors are obstacles to development of therapeutic agents that activate these receptors. However, it may be possible to exploit the high A1 “receptor reserve” for some actions of adenosine by use of weak (partial) agonists to target these actions while avoiding others for which receptor reserve is low. The presence of high receptor reserves for the anti-arrhythmic and anti-lipolytic actions of adenosine suggests that partial A1 agonists could be used as anti-arrhythmic and anti-lipolytic agents. In addition, allosteric enhancers of the binding of adenosine to A1 receptors could be used therapeutically to potentiate desirable effects of endogenous adenosine. Antagonists of the A1 receptor can increase urine formation, and because they do not decrease renal blood flow, are particularly useful to maintain glomerular filtration in patients having edema secondary to reduced cardiac function.
Export Options
About this article
Cite this article as:
Dhalla K. Arvinder, Shryock C. John, Shreeniwas Revati and Belardinelli Luiz, Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands, Current Topics in Medicinal Chemistry 2003; 3 (4) . https://dx.doi.org/10.2174/1568026033392246
DOI https://dx.doi.org/10.2174/1568026033392246 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High-Throughput Structural Biology in Drug Discovery: Protein Kinases
Current Pharmaceutical Design Analysis of Heart Rate Variability and Implication of Different Factors on Heart Rate Variability
Current Cardiology Reviews Vasopressin-Receptor Antagonists: A New Class of Agents for the Treatment of Hyponatremia
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Soybean and Processed Soy Foods Ingredients, and Their Role in Cardiometabolic Risk Prevention
Recent Patents on Food, Nutrition & Agriculture Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets 23Na Magnetic Resonance Imaging for the Determination of Myocardial Viability: The Status and the Challenges
Current Vascular Pharmacology Edging Toward Personalized Medicine
Current Pharmacogenomics Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Polymer Structures for Sensors and Actuators 1. Analyte Biosensor
Recent Patents on Materials Science New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients
Current Drug Safety An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews The Influence of Microneedles on the Percutaneous Penetration of Selected Antihypertensive Agents: Diltiazem Hydrochloride and Perindopril Erbumine
Current Drug Delivery EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry